Table 1. Antiproliferative properties of the synthetized compounds.
Compound | Conc. (μM) | Inhibition % ± SEM[Calculated IC50 value] a | |||
---|---|---|---|---|---|
HeLa | MCF7 | A431 | MRC5 | ||
2 | 10 | – b | – | 29.83 ± 2.36 | n.d. c |
30 | 30.24 ± 2.25 | – | 51.48 ± 1.87 | ||
3 | 10 | – | – | – | n.d. |
30 | 24.44 ± 2.51 | – | 47.71 ± 2.22 | ||
4a | 10 | 37.44 ± 2.44 | – | 34.92 ± 0.58 | n.d. |
30 | 68.28 ± 0.54 | 49.93 ± 0.63 | 47.92 + 1.24 | ||
[10.21 μM] | [>30 μM] | [>30 μM] | |||
4b | 10 | – | – | – | n.d. |
30 | – | – | – | ||
4c | 10 | – | – | – | n.d. |
30 | – | – | – | ||
4d | 10 | – | – | 24.68 ± 1.31 | n.d. |
30 | 45.45 ± 0.84 | 28.79 ± 1.51 | 26.13 ± 2.30 | ||
4e | 10 | 51.34 ± 0.62 | 34.13 ± 2.14 | 41.87 ± 1.92 | n.d. |
30 | 71.39 ±1.17 | 64.39 ± 1.15 | 55.47 ± 0.79 | ||
[14.80 μM] | [17.78 μM] | [22.76 μM] | |||
4f | 10 | 47.07 ± 1.06 | 61.87 ± 2.59 | – | n.d. |
30 | 97.30 ± 0.49 | 96.36 ± 0.44 | 29.21 ± 2.76 | ||
[10.68 μM] | [8.07 μM] | [>30 μM] | |||
4g | 10 | – | – | – | n.d. |
30 | 51.62 ± 2.04 | – | 23.24 ± 1.03 | ||
4h | 10 | – | 24.19 ± 2.00 | 23.71 ± 1.03 | n.d. |
30 | 92.85 ± 0.41 | 66.63 ± 1.19 | 42.59 ± 1.14 | ||
[11.68 μM] | [11.58 μM] | [>30 μM] | |||
4i | 10 | 47.24 ± 2.13 | – | 26.98 ± 0.87 | – |
30 | 98.38 ± 0.15 | 82.48 ± 0.85 | 94.70 ± 0.46 | 25.74 ± 2.94 | |
[13.85 μM] | [14.88 μM] | [11.75 μM] | [>30 μM] | ||
4j | 10 | 23.78 ± 2.27 | 30.96 ± 1.71 | 35.79 ± 1.53 | n.d. |
30 | 51.49 ± 1.92 | 43.48 ± 1.30 | 49.96 ± 1.43 | ||
4k | 10 | 25.33 ± 2.54 | – | – | n.d. |
30 | 38.09 ± 2.03 | 47.94 ± 1.15 | – | ||
4l | 10 | – | – | – | n.d. |
30 | 34.44 ± 2.14) | 33.29 ± 2.51 | 26.92 ± 1.75 | ||
5a | 10 | – | – | – | n.d. |
30 | 34.63 ± 2.14 | 39.95 ± 1.96 | 52.94 ± 0.70 | ||
5b | 10 | 40.54 ± 0.74 | – | 44.29 ± 0.73 | n.d. |
30 | 50.06 ± 1.13 | – | 44.71 ± 1.63 | ||
5c | 10 | – | – | – | n.d. |
30 | 36.57 ± 1.08 | 44.20 ± 1.54 | 58.09 ± 0.21 | ||
5d | 10 | 37.41 ± 1.16 | 26.05 ± 2.73 | – | n.d. |
30 | 46.76 ± 2.95 | 37.10 ± 2.35 | 49.14 ± 2.13 | ||
5e | 10 | 31.65 ± 2.53 | – | – | n.d. |
30 | 40.81 ± 2.35 | – | – | ||
5f | 10 | 90.47 ± 0.53 | 73.15 ± 1.39 | 72.94 ± 0.87 | 32.75 ± 2.49 |
30 | 95.17 ± 0.27 | 78.94 ± 0.55 | 70.98 ± 0.86 | 68.32 ± 0.76 | |
[5.08 μM] | [7.88 μM] | [6.77 μM] | [17.64 μM] | ||
5g | 10 | 85.62 ± 0.75 | 44.84 ± 2.19 | 47.32 ± 1.02 | 33.74 ± 1.74 |
30 | 95.55 ± 0.62 | 60.60 ± 1.97 | 73.60 ± 0.46 | 68.61 ± 1.22 | |
[8.69 μM] | [10.78 μM] | [10.68 μM] | [17.07 μM] | ||
5h | 10 | 75.26 ± 1.57 | 32.80 ± 2.59 | 43.15 ± 1.87 | 21.01 ± 1.58 |
30 | 86.44 ± 0.57 | 36.30 ± 1.26 | 51.76 ± 1.52 | 20.44 ± 1.29 | |
[12.11 μM] | [>30 μM] | [>30 μM] | [>30 μM] | ||
5i | 10 | – | – | – | n.d. |
30 | 24.55 ± 2.69 | 64.62 ± 1.71 | – | ||
5j | 10 | – | – | – | n.d. |
30 | 40.47 ± 2.39 | – | – | ||
5k | 10 | 26.28 ± 1.23 | – | – | n.d. |
30 | 34.55 ± 1.61 | – | – | ||
5l | 10 | – | – | – | n.d. |
30 | 26.54 ± 2.16 | – | –) | ||
Cisplatin | 10 | 42.61 ± 2.33 | 53.03 ± 2.29 | 88.54 ± 0.50 | 72.30 ± 2.30 |
30 | 99.93 ± 0.26 | 86.90 ± 1.24 | 90.18 ± 1.78 | 70.65 + 1.34 | |
[12.43 μM] | [9.63 μM] | [2.84 μM] | [4.51 μM] |
a Mean value from two independent determinations with five parallel wells, standard deviation less than 15%.
b Inhibition values <20% are not presented for clarity.
c n.d.: not determined.